March 10, 2020 / 6:38 PM / a month ago

BRIEF-Gilead Presents Longer-Term Results From The DISCOVER Trial Of Descovy

March 10 (Reuters) - Gilead Sciences Inc:

* GILEAD PRESENTS 96-WEEK DISCOVER TRIAL DATA DEMONSTRATING FAVORABLE RENAL AND BONE SAFETY PROFILE OF DESCOVY® FOR HIV PREP IN AT-RISK POPULATIONS

* SEPARATE ANALYSIS OF DISCOVER TRIAL DEMONSTRATED DESCOVY & TRUVADA WERE EFFECTIVE & WELL-TOLERATED IN BLACK & HISPANIC/LATINX PARTICIPANTS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below